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Research articleAdjuvant glycerol is not beneficial in experimental 
pneumococcal meningitis
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Abstract
Background: Bacterial meningitis in children causes high rates of mortality and morbidity. In a recent clinical trial, oral 
glycerol significantly reduced severe neurological sequelae in paediatric meningitis caused by Haemophilus influenzae 
type b, and a tendency towards a benefit of adjunctive glycerol was seen in pneumococcal meningitis.
Methods: Here we examined the effects of glycerol in pneumococcal meningitis of infant rats and adult mice. All 
animals received ceftriaxone, and glycerol or placebo. Brain damage, hearing loss, and inflammatory parameters were 
assessed.
Results: Clinically and by histopathology, animals treated with glycerol or placebo did not differ. While both groups 
showed equally high levels of matrix metalloproteinase-9 at 24 h after infection, a significant difference in favour of 
glycerol was observed at 40 h after infection. However, this difference in matrix metalloproteinase-9 in late disease did 
not result in an improvement of histopathologic parameters.
Conclusion: No benefit of adjunctive glycerol was found in these models of pneumococcal meningitis.
Background
The outcome of pneumococcal meningitis (PM) in chil-
dren has essentially not improved since the introduction
of antibiotics [1]. A major cause of neurological compli-
cations is the excessive inflammatory reaction of the host
[2,3]. To diminish this reaction, dexamethasone (DXM) is
advocated as adjuvant therapy to antibiotics.
Secondary to the inflammatory reaction, brain oedema
and increased intracranial pressure are life-threatening
events in PM. Hyperosmolar agents, such as glycerol
(GLY), have been suggested to antagonize these processes
[4]. Important new information arrived from a large (n =
654) randomized, prospective and double-blind trial in
which intravenous DXM was put vis-à-vis oral GLY and
placebo [2]; GLY reduced severe neurological sequelae
significantly in Haemophilus influenzae type b (Hib)
meningitis, whereas DXM did not. In PM, a positive
trend for GLY was observed on death or severe neurolog-
ical sequelae. Data on GLY in adults with PM do not exist.
Evidently, additional studies are warranted to further elu-
cidate the pros and cons of GLY in PM [2,3]. Here we
examined the effects of adjuvant GLY in PM of infant rats
and adult mice.
Methods
Infant rat model of PM
An established model of infant rat PM was used [5,6].
Eleven days old Wistar rats were infected by intracister-
nal injection of 10 μl saline containing 1.4 × 106 ± 5.3 ×
105 colony forming units (cfu)/ml Streptococcus pneumo-
niae serotype 3 (n = 34), which has been isolated from a
patient with invasive disease [7]. Control animals were
injected with the same volume of sterile saline (n = 8).
Animals were weighed and their clinical status was
assessed at 18 and 40 h after infection [5,6]. Cerebrospi-
nal fluid (CSF) was obtained at 18 h after infection by
intracisternal puncture and 5 μl were cultured quantita-
tively [5]. Additional CSF was obtained, when possible, 24
h and 40 h after infection to assess the levels of matrix
metalloproteinase (MMP)-9.
When starting the treatment at 18 h after infection, the
animals were randomized to receive either 50 μl GLY 60%
per os (n = 17 for infected and n = 4 for control animals)
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or 50 μl placebo (carboxymethylcellulose 2%) per os (n =
17 for infected and n = 4 for control animals) at 18 h, 24 h,
30 h and 38 h after infection. This corresponds to the
dosing used in the clinical study [2]. Antibiotic therapy
was started at 18 h after infection with 100 mg/kg body
weight ceftriaxone subcutaneously administered to all
animals twice daily. At 40 h after infection, the animals
were sacrificed with an overdose of pentobarbital and
brains were dissected.
All animal studies were approved by the Animal Care
and Experimentation Committee of the Canton of Bern,
Switzerland.
Assessment of MMP-9 levels in CSF
Levels of MMP-9 were assessed by gel zymography as
previously described in detail [5,7]. The levels of the
inducible MMP-9 were expressed as the percentage of the
constitutively expressed MMP-2 [7].
Histopathology
For the assessment of an effect on acute brain damage a
higher inoculum (4.0 × 106 ± 0.0 cfu/ml, n = 56) was used
in separate experiments. The histological assessment of
brain damage was performed as previously described [5].
Adult mouse model of PM
The mouse model used is well established [8]. Meningitis
was introduced in C57BL/6 mice by injection of 15 μl of a
bacterial suspension containing 107 cfu/ml of Streptococ-
cus pneumoniae D39 into the cisterna magna under
anaesthesia. At 18 and 24 h after infection, animals were
examined clinically, randomized for 250 μl GLY 85% per
os (n = 8) or placebo (carboxymethylcellulose 2%) (n = 8)
and treated with ceftriaxone (100 mg/kg intraperitone-
ally). Effective administration of GLY was documented by
an increase in serum osmolality in comparison to placebo
treated animals (mean increase 6%). CSF was sampled by
puncture of the cisterna magna. All mouse experiments
were approved by the government of Upper Bavaria, Ger-
many.
Determination of hearing thresholds
Hearing thresholds were determined by measuring audi-
tory brainstem responses in mice as described previously
[9]. The lowest stimulus intensity that elicited auditory
brainstem responses was considered the hearing thresh-
old.
Histology of the inner ear
The histological assessment of inner ear damage was per-
formed as described previously [9]. Seven μm mid-modi-
olar sections of mice temporal bones were deparaffinized,
re-hydrated, and stained with Mayer's haematoxylin and
eosin.
Statistical analyses
Statistical analyses were performed using Prism (Graph-
Pad Software, San Diego, CA USA) or SYSTAT. Median
[range] is presented for not normally distributed data
while mean ± SD is given for normally distributed data.
Kruskal-Wallis test was used to compare three or more
groups with not normally distributed data. Mann-Whit-
ney and unpaired t test was used for not normally and
normally distributed data, respectively. Survival curves
were analyzed with the Log-rank (Mantel-Cox) Test. P <
0.05 was considered statistically significant. Animals that
died unobserved or were euthanized for ethical reasons
were excluded from all analyses.
Results
Infant rat model
Clinical parameters of the disease
18 h after infection, all infected animals showed high bac-
terial load in the CSF. The bacterial load of animals
treated with placebo vs animals treated with GLY did not
differ (2.9 × 107 [4.0 × 106 - 7.0 × 107] cfu/ml for placebo
vs 1.2 × 107 [6.0 × 106 - 1.1 × 108] cfu/ml for GLY; P = ns).
The activity score (4.0 [4.0-4.0] for placebo vs 4.0 [4.0-4.0]
for GLY at both time points) and weight loss (18 h after
infection: 0.1 [-1.0-1.5] g for placebo vs 0.1 [-0.8-1.9] g for
GLY; P = ns and 40 h after infection: -1.5 [-3.3-1.1] g for
placebo vs -1.1 [-2.7-3.6] g for GLY; P = ns) did not differ
between the treatment groups. Weight of control vs
infected animals was significantly different (18 h after
infection: 1.8 [0.7-2.7] g for controls vs 0.1 [-1.0-1.9] g for
infected animals, P < 0.001 and 40 h after infection: 4.9
[1.2-6.4] for controls vs -1.2 [-3.3-3.6] g for infected ani-
mals, P < 0.001).
Assessment of MMP-9 levels in CSF
At 24 h after infection the levels of MMP-9 did not differ
between the placebo- and the GLY- treated animals (Fig-
ure 1). After that time-point, MMP-9 levels decreased
significantly from 23% to 5% and from 23% to 2% for the
placebo and GLY group, respectively (P < 0.001 for pla-
cebo and GLY animals). The MMP-9 levels of the GLY-
treated rats were significantly lower than in the placebo
group 40 h after infection (P < 0.05; Figure 1).
Histopathology
Among the animals infected with the low inoculum, 27%
showed apoptosis in the hippocampus and 42% showed
cortical damage. No difference was found between the
control and infected animals (Kruskal-Wallis test: P = ns
for apoptosis and cortical damage). When the higher
inoculum was used, 91% of the infected animals showed
apoptosis and 62% cortical damage (Kruskal-Wallis test:
P < 0.01 for apoptosis, P < 0.05 for cortical damage).
Experiments with the high inoculum showed high mor-
tality (60% for placebo vs 65% for GLY; Log-rank test: P =
ns) which reflects a more severe disease. Adjuvant GLY (n
= 11) vs placebo (n = 10) did not have an effect on apop-
tosis (0.5 [0.1-1.1 for placebo vs 0.6 [0.0-1.8] for GLY, P =
ns) or cortical damage (1.0 [0.0-8.1] for placebo vs 0.3
[0.0-4.2] for GLY,P = ns).
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Adult mouse model of PM
At 18 h after infection, all animals showed clinical signs of
infection by assessment of clinical score, weight loss, and a
reduction of explorative activity. No difference in mortality
was observed as the survival rate was 5/8 animals in the pla-
cebo and 4/8 animals in the GLY group (P = ns). Nor were
differences observed in the clinical score (7.0 ± 2.6 for pla-
cebo vs 9.0 ± 2.9 for GLY, P = ns), explorative activity (16.6 ±
11.6 fields/2 minutes for placebo vs 10.0 ± 0.8 fields/2 min-
utes for GLY, P = ns), or weight loss (-17.5 ± 3.3% for placebo
vs -18.7 ± 5.0% for GLY, P = ns). Measurements of brain
albumin concentration reflect the blood brain barrier (BBB)
breakdown. The concentration in brain lysates of uninfected
animals was 44.0 ± 4.0 ng/ml and was increased in infected
mice without differences between GLY-treated and placebo-
treated mice (433.8 ± 262.0 vs 338.5 ± 187.7 ng/ml brain
lysate). Moreover, CSF cell counts were similar between
both groups (5700 ± 3381 cells/μl for placebo vs 5850 ± 714
cells/μl for GLY, P = ns).
The hearing thresholds were elevated in all infected
animals and did not differ between the treatment groups.
Similarly, histological differences in the inner ear were
not observed. Granulocytic infiltration occurred equally
in the perilymphatic space of the treated and non-treated
animals.
Discussion
The potential effects of adjuvant GLY in PM were evalu-
ated in infant and adult rodent models of PM by assessing
clinical, histopathological and functional outcome. Since
GLY did not show an advantage over placebo in these
parameters, this observation may partially explain why
GLY did not significantly improve the outcomes of PM in
children. In contrast, in Hib meningitis there is good evi-
dence for using GLY, because it reduces severe neurologi-
cal sequelae [1,2].
The aim of this study was to evaluate the effect of
adjunctive therapy with oral glycerol in experimental
pneumococcal meningitis in children and adults, using an
infant rat and an adult mouse model, respectively. A
direct comparison between glycerol effects on rats and
mice was not the goal of the study and, thus, variations
between the models should not affect the key issues of the
study. Both models that were used are well-defined and
have been optimized to develop the typical clinical, func-
tional and histopathological features of pneumococcal
meningitis in the respective age group. In the infant rat
model, we regularly found clinical signs of meningitis,
CSF pleocytosis, and histopathologic alterations such as
apoptotic hippocampal damage. While in the adult
model, we found clinical signs of meningitis, CSF pleocy-
tosis, blood brain barrier damage, and hearing loss with
cochlear damage. In the adult mouse model, we investi-
gated hearing loss, cochlear damage, and the clinical con-
dition (clinical score and motor activity) with a main
focus on hearing loss and cochlear damage. Earlier stud-
ies showed that brain damage including hippocampal
apoptosis is not a consistent finding in the adult mouse
model but is regularly seen in the infant rat model [8].
Therefore, brain damage was not assessed histologically
in the adult mouse model in this study. With respect to
the drug dosage, we performed studies using the same
glycerol dosage (10 mg/kg body weight per os, bid) in
both models. However this led to excessive and early
mortality in infant rats which precluded the assessment
of apoptosis. These observations show exemplarily that
models of infectious diseases need to be adapted for the
assessment of clinically relevant outcome measurements.
Three clinical trials evaluated the effect of oral GLY on
hearing impairment in bacterial meningitis [2,4,10]. A
statistical difference for severe hearing impairment (> 80
dB) in GLY vs no GLY recipients was shown in one study
[4] but has not later been confirmed [2,10], which fits the
negative results of our adult mouse model examining
hearing loss 40 h after infection. Since cochlear inflam-
mation, a key factor for subsequent cochlear damage,
appeared similarly in both treatment groups, it seems
unlikely that a long-term benefit of GLY on hearing loss
was missed in our study.
Previously, damage in the hippocampal dentate gyrus
after GLY administration was found in a rabbit model of
PM; GLY increased apoptosis, while placebo did not [11].
The present study does not support that finding, but did
not show a protective effect either. No protective effect of
GLY against meningitis-induced cortical damage or BBB
Figure 1 MMP-9 levels in cerebrospinal fluid of rats with meningi-
tis treated with placebo or glycerol. The amounts of MMP-9 did not 
differ in the acute phase of the disease at 24 h after infection. Subse-
quently, the levels decreased approximately 10-fold in both treatment 
groups. At 40 h after infection glycerol-treated animals showed signif-
icantly (P < 0.05) lower levels of MMP-9 than placebo-treated animals 
(Log2 scale).
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breaching was observed either. Combined, our study does
not provide evidence for a neuroprotective action of adju-
vant GLY therapy in PM.
MMPs degrade the extracellular matrix including the
subendothelial basement membrane which forms the
BBB and are considered as effector molecules of BBB
breakdown and leukocyte extravasation in bacterial men-
ingitis [7]. Regarding bacterial meningitis, MMP-9 seems
especially interesting, because its concentration increases
in CSF and the brain tissue of patients and animals in an
experimental setting [6,12-14]. MMP antagonism in
experimental models has reduced brain damage and BBB
disruption [6,12-14].
In this study, the placebo and the GLY groups showed
equally high levels of MMP-9 24 h after infection. Subse-
quently, the levels decreased approximately 10-fold in
both treatment groups until 40 h after infection when the
GLY group showed significantly lower concentrations as
compared with the non-GLY group of animals. Despite
this divergence in MMP-9 levels in late disease, no differ-
ence was observed in the extent of neuronal damage or
BBB disruption. It is conceivable that neuronal and vas-
cular damage develop in the early phase of disease, when
the MMP-9 levels are equally high. A reduction of MMP-
9 at a later stage is probably too late to influence the
already launched detrimental process.
Conclusion
We detected no benefit of adjunctive GLY in an infant
and adult animal model of PM. Thus, due to the limited
number of tools besides antimicrobials to improve the
prognosis of PM, the search for new approaches needs to
be continued.
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